Close Menu

People in the News

Jan 21, 2020

Zymergen: Jay Flatley

Jay Flatley has joined the board of directors of Zymergen, serving as lead independent director. He is the chairman of the board of Illumina. From 1999 until 2016, Flatley was the CEO of Illumina, and until the end of 2019, he was the company's executive chairman.

Jan 21, 2020

GenMark Diagnostics: James McNally

GenMark Diagnostics said that on Jan. 9, it notified James McNally, its senior vice president of marketing and business development, that his employment with the firm would cease on Jan. 10.

In a filing with the US Securities and Exchange Commission, GenMark also said that on Jan. 14, it entered into a separation agreement and general release with McNally. In accordance with the agreement, McNally is entitled to benefits, including a gross lump sum payment equal to six months of his base salary in effect as of the separation date; an amount equal to McNally’s target bonus percentage under the firm's 2019 bonus plan multiplied by a percentage tied to the achievement of the company-level performance targets under the plan; and an aggregate of 35,702 restricted stock units held by McNally as of the separation date.

Jan 21, 2020

Qlucore: Johan Thiel and Boel Sundvall

Qlucore has named Johan Thiel and Boel Sundvall to its board of directors. Thiel is a longtime entrepreneur who served for six years as CEO of MIPS, a Swedish company known for making a "brain protection system" for bicycling and snowboarding helmets that reduces rotational forces that often lead to concussions. Sundvall comes from a background in corporate finance, investor relations, and communications, including with MIPS.  

Jan 15, 2020

Tempus: Ari Caroline, Iker Huerga

Tempus has hired Ari Caroline as senior VP of health strategy and Iker Huerga as VP of data engineering and strategy. Both founded healthcare artificial intelligence firm Da'At AI, an early-stage startup that Tempus recently acquired the entire team of. Prior to launching Da'At, Caroline was chief analytics officer at Memorial Sloan-Kettering Cancer Center in New York, while Huerga served as director of engineering and applied machine learning for MSK.

Jan 15, 2020

Illumina: Jay Flatley

Jay Flatley has become chairman of the board of directors at Illumina. Until the end of 2019, he was executive chairman, and from 1999 until mid-2016, he was Illumina's CEO. Previously, he was president and CEO of Molecular Dynamics, now part of GE Healthcare. Before that, he was VP of engineering and strategic planning at Plexus Computers, executive VP at Manning Technologies, and held various positions at Spectra Physics.

Jan 14, 2020

Myriad Genetics: Thomas Slavin

Thomas Slavin will be senior VP of medical affairs at Myriad Genetics' oncology division. Starting March 2, he will report to Nicole Lambert, president of Myriad Oncology, and be in charge of Myriad's portfolio of molecular and companion diagnostic products and services for oncology. Slavin is board certified in clincial genetics, medical diagnostics, and pediatrics, and most recently was an assistant professor in City of Hope National Medical Center's medical oncology & therapeutics research and population sciences division. 

Jan 13, 2020

T2 Biosystems: Tony Pare

T2 Biosystems has promoted Tony Pare to the newly created position of chief commercial officer, effective immediately. Pare previously served as vice president and general manager of T2 Biosystems' international business. Prior to that, he held senior business development positions at Haemonetics and Hemanext.

Jan 13, 2020

Spartan Bioscience: Dirk Sibbing; Gilles Montalescot; Marco Valgimigli; Davide Capodanno

Spartan Bioscience has establishd a scientific advisory board in Europe. The members are Dirk Sibbing, an inverventional cardiologist and professor of cardiology at Ludwig-Miximilians University in Munich; Gilles Montalescot, a professor of cardiology at the University of Paris VI, and director of the cardiac care unit at Pitié-Salpêtrière Hospital, Paris; Marco Valgimigli, associate professor of cardiology and senior interventional cardiology at Inselspital Universitätsspital in Bern, Switzerland; and Davide Capodanno, associate professor of cardiology at the University of Catania, Italy, and interventional cardiologist, Azienda ""Policlinico-Vittorio Emanuele" in Catania. The company added that a North American team will be announced in March at the American College of Cardiology conference. 

 
Jan 13, 2020

Foundation Medicine: Ritesh Khullar

Ritesh (Tesh) Khullar has been appointed as chief commercial officer of Foundation Medicine, effective Jan. 20. He joins the Roche subsidiary from Flatiron Health, where he was responsible for leading and scaling provider service offerings. Prior to that, he was the national VP and general manager of sales and account management at McKesson Specialty Health. He also held various roles at Oncology Therapeutics Network. Khullar holds an MBA from the University of San Francisco and a BA in history with a minor in computer science and engineering, political science, and law and society from the University of California, San Diego.

Jan 13, 2020

Twist Bioscience: Patrick Weiss, Bill Banyai

Twist Bioscience has promoted Patrick Weiss to chief operating officer from senior VP of R&D and general manager of data storage. It has appointed Bill Banyai as senior VP of advanced development and general manager of data storage.

Before helping to build Twist's operational infrastructure, Weiss served as President and CEO of Operon Biotechnologies. He also founded Xeragon, an RNA synthesis and bioinformatics firm acquired by Qiagen in 2002. He holds a master's degree in chemistry from the Swiss Federal Institute of Technology and is an author on several patents.

Banyai is a cofounder and director of the company and will maintain his board seat. He led the integration of Genome Compiler, which Twist acquired in 2016 and has overseen facilities expansions. Banyai previously served as VP of hardware at Complete Genomics. He holds a doctorate in optical science from the University of Arizona.

Jan 10, 2020

Oxford Nanopore Technologies: John O'Higgins, Clive Brown

John O'Higgins and Clive Brown have joined the board of directors of Oxford Nanopore Technologies, the company said this week. According to a regulatory filing, the appointments were made last September. Brown is the company's chief technology officer. O'Higgins, who joined the board as a non-executive director, is the former CEO of Spectris, an instrumentation and controls company. He holds non-executive roles at several other companies and is a member of the corporate advisory board of Great Ormond Street Hospital Charity in the UK.

Jan 10, 2020

Transplant Genomics: John Holman

Mansfield, Massachusetts-based Transplant Genomics has appointed John Holman as VP of Medical Affairs. He will replace Roy First, who will continue working as senior clinical advisor. Prior to TGI, Holman served as VP of Immunology and Translational Medicine at Quark Pharmaceuticals. He has also served as VP of clinical research at Myriad Genetics for three years. Prior to Myriad, Holman served as executive medical director as Astellas. 

Jan 09, 2020

Bio-Rad Laboratories: Dara Grantham Wright

Bio-Rad Laboratories has appointed Dara Grantham Wright as executive vice president of its clinical diagnostics group. She will replace John Hertia, who retired Dec. 31, 2019. Grantham Wright most recently served as VP and general manager of the protein and cell analysis biosciences division at Thermo Fisher Scientific. She has also held senior positions at Affymetrix, Boreal Genomics, and Becton Dickinson.

Jan 08, 2020

Genialis: Luka Ausec, Bruce Lefker

Genialis has promoted Luka Ausec to the position of chief discovery officer. He formerly served as director of projects for the San Ramon, California-based company. Genialis also added Bruce Lefker to its scientific advisory board. Lefker is a medicinal chemist with 30 years of experience working at Pfizer.

Jan 08, 2020

Genome Medical: Amy McLaughlin

Genome Medical has hired Amy McLaughlin as chief commercial officer. McLaughlin is leading sales, business development, marketing, and managed care for the telegenomics firm, which is in the process of expanding its commercial team. She previously served as senior vice president of business development for acute care management and staffing company Vituity.

Jan 08, 2020

Cytox: Ian Gilham

Cytox has appointed Ian Gilham its chairman of the board. He was CEO of Axis-Shield until Alere acquired the company in 2011. He also held positions at Amersham International, Abbott Laboratories, and GlaxoSmithKline. Gilham is currently non-executive chairman of Horizon Discovery, Genedrive, and Biosurfit and previously was chairman of Multiplicom and Elucigene. Oxford, UK-based Cytox develops noninvasive risk assessment and patient stratification tools for Alzheimer's disease and dementia. 

Jan 07, 2020

ArcherDx: Mark Massaro

ArcherDx has appointed Mark Massaro its CFO. He was most recently managing director and senior research analyst covering the diagnostics and life science tools sector at investment bank Canaccord Genuity. He also held corporate finance and financial reporting positions at Dell EMC and Fidelity Investments. 

Jan 06, 2020

NuProbe Global: Yingshuang Chai

NuProbe Global has named Yingshuang Chai CEO and chairman of the board of directors. Chai was cofounder and CEO of CarrierGene Biotech, a Chinese genetic testing firm that recently merged with NuProbe. He brings 20 years of experience in market operations, having served as the national clinical business director at Life Technologies China and national director of clinical strategy and development at Thermo Fisher China.

Jan 02, 2020

Columbia University: Wendy Chung

Wendy Chung has become chief of the Division of Clinical Genetics in the Department of Pediatrics at Columbia University Irving Medical Center. She succeeds Kwame Anyane-Yeboa, who will continue as professor of pediatrics in clinical genetics. Chung is the Kennedy Family Professor of Pediatrics at Columbia.

Dec 31, 2019

Enzo Biochem: Rebecca Fischer

Enzo Biochem has appointed Rebecca Fischer to its board of directors, effective immediately. Her appointment as an independent director follows a process as part of the company's focus on board compositions, refreshment, and diversity. Fisher's appointment, Enzo said, will be a valuable contribution to its women's health business. She replaces Gregory Bortz who retired from the board. Dov Perlysky, who has been on the board since 2012, will replace Bortz as lead independent director of Enzo. 

Fisher has been appointed to Enzo's audit, compensation, and nominating/governance committees and will be chair of the audit committee. She is currently CFO of Bellevue Hospital. She began her career there in 2003 and was promoted to deputy CFO in 2016 before becoming CFO in 2017.

Dec 23, 2019

SGI-DNA: Brian Donnelly

Synthetic biology firm SGI-DNA announced the appointment of Brian Donnelly to the newly created position of chief commercial officer. Donnelly will be responsible for global sales, marketing, customer service and support, and business development.

Donnelly comes to the firm from Illumina, where he most recently led Illumina's global service organization. During his time at Illumina, Brian also led the global commercial strategy and global clinical marketing teams. He has also held commercial and operational roles at Sequenom, GlaxoSmithKline, and Allergan. He holds MBA and JD degrees from Rutgers University.

Dec 23, 2019

Invicro/Konica Minolta Precision Medicine: Matthew Silva and Jack Hoppin

Invicro, a Konica Minolta Company focused on imaging for translational drug discovery and development, has appointed Matthew Silva as CEO. Silva, who will also join Invicro's board, joined the company in 2012 and was most recently executive vice president of scientific applications. He has also worked in leadership positions at Vertex, Amgen, Millenium, and Takeda Pharmaceuticals.

Silva will replace Jack Hoppin as Invicro's CEO. Hoppin is a cofounder of the company and will move from his role as Invicro CEO to be the president of Konica Minolta Precision Medicine. Hoppin will also serve on the boards of both companies.

Dec 19, 2019

RareCyte: David Kabakoff, Andy Schwab

In conjunction with RareCyte's recent financing round, David Kabakoff and Andy Schwab have joined the company's board of directors. Kabakoff is a partner at HealthQuest Capital and Schwab is a managing partner at 5AM Ventures. Both companies are RareCyte investors.

Dec 19, 2019

Laboratory for Advanced Medicine: Aarif Nakhooda

Laboratory for Advanced Medicine has appointed Aarif Nakhooda as CFO. He was most recently CFO of Amazon Retail Singapore. He also previously served as head of finance for Amazon Prime worldwide and Amazon Prime Transportation. Prior to joining Amazon, he worked in transaction advisory services for Ernst & Young. Based in Irvine, California, Laboratory for Advanced Medicine is commercializing tests for the early detection of cancer from a blood draw by using AI technology to identify cfDNA methylation patterns.

Dec 18, 2019

XCR Diagnostics: Chuck Morrison

XCR Diagnostics has appointed Chuck Morrison to its board of directors. Morrison was a director at GenePOC and aided in the acquisition of that firm by Meridian Bioscience earlier this year. He earlier was a director of business development at PerkinElmer.

Pages

Researchers have sequenced the genome of the depth-dwelling giant squid.

Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.

 

Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.

In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.